These noteworthy results provided a rationale for the ongoing pivotal phase II study in NSCLC (NCT03940703, INSIGHT 2), evaluating the combination of tepotinib with osimertinib in patients with advanced EGFR-mutant METamp NSCLC with acquired resistance to first-line osimertinib (19). Here, EGFR is linked to non-small cell lung carcinoma.